ricochet64 / Shutterstock.com
2 November 2021Big Pharma
English High Court denies Mylan a stay in Neurim litigation
Mylan has failed to secure a stay in litigation centring on a melatonin-based insomnia patent at the English High Court.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
Europe
26 May 2022 The case reinforced the need for interim injunction applications to be made as quickly as possible, explains Lydia Birch of EIP.
Americas
8 December 2020 Neurim Pharmaceuticals has won its case against generics drug maker Mylan at the English High Court, which held that its patent for a treatment for insomnia was valid and had been infringed in a ruling handed down on December 4.
Big Pharma
25 January 2022 Mylan has been allowed to challenge Neurim's melatonin patent at trial following a ruling by the High Court of England and Wales that the generic drug maker did not contravene the legal principle of estoppel.
Editor's picks
Editor's picks
Europe
26 May 2022 The case reinforced the need for interim injunction applications to be made as quickly as possible, explains Lydia Birch of EIP.
Americas
8 December 2020 Neurim Pharmaceuticals has won its case against generics drug maker Mylan at the English High Court, which held that its patent for a treatment for insomnia was valid and had been infringed in a ruling handed down on December 4.
Big Pharma
25 January 2022 Mylan has been allowed to challenge Neurim's melatonin patent at trial following a ruling by the High Court of England and Wales that the generic drug maker did not contravene the legal principle of estoppel.
Europe
26 May 2022 The case reinforced the need for interim injunction applications to be made as quickly as possible, explains Lydia Birch of EIP.
Americas
8 December 2020 Neurim Pharmaceuticals has won its case against generics drug maker Mylan at the English High Court, which held that its patent for a treatment for insomnia was valid and had been infringed in a ruling handed down on December 4.
Big Pharma
25 January 2022 Mylan has been allowed to challenge Neurim's melatonin patent at trial following a ruling by the High Court of England and Wales that the generic drug maker did not contravene the legal principle of estoppel.